Cancer Care
-
Thyme Care Secures $125 Million, Valued Over $2 Billion
Thyme Care, a virtual cancer navigation platform, has secured $125 million in Series E funding, boosting its valuation to over $2 billion. This capital will fuel the creation of a new parent company, Thyme Companies, aimed at addressing disparities in cancer care access, financing, and delivery. Thyme Companies will focus on critical areas like drug affordability through biosimilars and improving clinical trial enrollment. The company, now profitable and generating positive cash flow, is poised for strategic growth and innovation in tackling complex oncology challenges.
-
Sun Life to Proactively Offer Second Opinions on Cancer Diagnoses for Claimants
Sun Life is proactively offering second opinions for cancer diagnoses, a significant shift from traditional insurance. This initiative aims to provide members with treatment certainty from the start, streamlining the claims process and improving health outcomes. The insurer believes this approach will enhance member loyalty, reduce long-term costs by preventing misdiagnoses and suboptimal treatments, and align with value-based care principles. This move positions Sun Life as a leader in patient-centric cancer care.
